BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 68 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q3 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,118,914 | -43.2% | 3,525,754 | 0.0% | 0.20% | -40.8% |
| Q2 2023 | $17,805,058 | +263.7% | 3,525,754 | +36.1% | 0.34% | +202.7% |
| Q1 2023 | $4,894,919 | +5.0% | 2,589,904 | 0.0% | 0.11% | +16.8% |
| Q4 2022 | $4,661,827 | +6.5% | 2,589,904 | 0.0% | 0.10% | +2.2% |
| Q3 2022 | $4,377,000 | -31.3% | 2,589,904 | 0.0% | 0.09% | -45.3% |
| Q2 2022 | $6,371,000 | -11.2% | 2,589,904 | 0.0% | 0.17% | +8.3% |
| Q1 2022 | $7,174,000 | -48.0% | 2,589,904 | 0.0% | 0.16% | -35.4% |
| Q4 2021 | $13,804,000 | -37.0% | 2,589,904 | 0.0% | 0.24% | -20.1% |
| Q3 2021 | $21,911,000 | -30.6% | 2,589,904 | 0.0% | 0.30% | -40.0% |
| Q2 2021 | $31,571,000 | -49.8% | 2,589,904 | 0.0% | 0.51% | -46.5% |
| Q1 2021 | $62,831,000 | -24.3% | 2,589,904 | 0.0% | 0.95% | -18.4% |
| Q4 2020 | $83,006,000 | +6.0% | 2,589,904 | 0.0% | 1.16% | -19.0% |
| Q3 2020 | $78,293,000 | -28.3% | 2,589,904 | 0.0% | 1.43% | -32.7% |
| Q2 2020 | $109,190,000 | +69.0% | 2,589,904 | 0.0% | 2.13% | +4.3% |
| Q1 2020 | $64,618,000 | – | 2,589,904 | – | 2.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $5,830,000 | 0.29% |
| K2 PRINCIPAL FUND, L.P. | 1,031,511 | $1,743,000 | 0.20% |
| Boxer Capital, LLC | 2,014,858 | $3,405,000 | 0.19% |
| DAFNA Capital Management LLC | 313,600 | $530,000 | 0.14% |
| Newtyn Management, LLC | 350,000 | $592,000 | 0.13% |
| Artal Group S.A. | 1,646,517 | $2,783,000 | 0.12% |
| Bellevue Group AG | 4,717,113 | $7,972,000 | 0.11% |
| MPM BioImpact LLC | 239,888 | $405,000 | 0.10% |
| RA Capital Management | 2,589,904 | $4,377,000 | 0.09% |
| Beacon Capital Management, LLC | 35,615 | $88,000 | 0.03% |